November 2nd, 2026Invivyd Unveils Measles Antibody Candidate VMS063 at IDWeek 2026Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.Read more
November 2nd, 2026GLP-1 Use Tied to Lower Diabetes, CV Risk vs Metformin in PrediabetesIn more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.Read more
November 2nd, 2026Sphingolipid Profiling May Help Distinguish IPF From Fibrotic HPSphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.Read more
November 2nd, 2026FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRPThe FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).Read more
November 2nd, 2026Occasional Cannabis Use Linked to 40% Higher Odds of StrokeIn nearly 443,000 US adults, both low-frequency and heavy cannabis use were linked to higher odds of cardiovascular disease, led by stroke.Read more
November 2nd, 2026Separating Depression From Hypersomnia: David T. Plante, MD, PhDClinicians separate idiopathic hypersomnia from depression-related sleepiness and interpret real-world and trial data for better outcomes.Read more
November 2nd, 2026Rosacea's Textbook Redness May Hide Cases in Patients of ColorErythema-based criteria miss skin of color, urging ROSCO phenotyping to improve diagnostic equity in dermatology.Read more
November 2nd, 2026Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 YearsNew abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.Read more